Sonova, is aiming to consolidate its market leadership with an agreed $489m cash offer for Advanced Bionics Corporation of the US. This deal will see Sonova become the first global hearing healthcare company with a strong worldwide presence in hearing instruments and cochlear implant systems. Advanced Bionics, founded in 1993 has grown to annual sales of $117m last year. The manufacturer is present in more than 30 countries and says it is the world number two in its market, with an 18 per cent share. Sonova said it expected to boost Advanced Bionics’ sales through access to its technology and distribution networks as well as greater financial resources. The group predicted it would double Advanced Bionics’ sales in the next three to five years and lift operating profit margins to at least 20 per cent. “With this transaction, Sonova adds a new source of sustainable business growth and enhances its position as the leading provider of hearing healthcare solutions”, Valentin Chapero, Sonova’s chief executive said. Advanced Bionics will remain an independent business unit within the Group but will share all the integral elements that have been driving the success of Sonova over the last decade.Moreover, the Sonova Group increased its sales by 18.2% in Swiss francs in the first six months to CHF 709 million (€ 616 millions). All regions and brands, as well as the recently launched products, contributed to organic sales growth in local currencies of 17.5%. "With 17.5% organic sales growth and 4.3% growth from acquisitions, Sonova further expanded its market share", explains the manufacturer. "The recently launched Exélia Art, Audéo YES and Passport hearing systems made a significant contribution to sales growth."